Sorrento Therapeutics, Inc.

OTCPK:SRNE.Q Stock Report

Market Cap: US$60.4m

Sorrento Therapeutics Balance Sheet Health

Financial Health criteria checks 0/6

Sorrento Therapeutics has a total shareholder equity of $-198.0M and total debt of $142.1M, which brings its debt-to-equity ratio to -71.8%. Its total assets and total liabilities are $456.7M and $654.6M respectively.

Key information

-71.8%

Debt to equity ratio

US$142.10m

Debt

Interest coverage ration/a
CashUS$80.64m
Equity-US$197.96m
Total liabilitiesUS$654.65m
Total assetsUS$456.69m

Recent financial health updates

Recent updates

Sorrento unit Scilex pre-emptively pays off remaining notes for $39.7M

Sep 29

Sorrento Sofusa drug delivery system shows promise vs subcutaneous injection in trial

Sep 15

Sorrento stock rises 13% on FDA fast track status for low back pain therapy SP-103

Aug 31

Sorrento achieves positive results in pivotal trial for abivertinib in NSCLC

Aug 23

Sorrento's unit Scilex inks distribution deal for pain drug ZTlido with CH Trading

Aug 17

Is Sorrento Therapeutics (NASDAQ:SRNE) A Risky Investment?

Jul 22
Is Sorrento Therapeutics (NASDAQ:SRNE) A Risky Investment?

Sorrento Therapeutics: The Enigma

Jul 15

Sorrento Therapeutics subsidiary Scilex to acquire Ancora Medical

Jul 07

Sorrento Therapeutics: Sales Are Up But EY Identifies Internal Control Issues

Mar 15

Sorrento Therapeutics: Wide Oncology Pipeline, And Watch Out For COVID Updates

Oct 09

Financial Position Analysis

Short Term Liabilities: SRNE.Q has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: SRNE.Q has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: SRNE.Q has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: SRNE.Q's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SRNE.Q has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: SRNE.Q has less than a year of cash runway if free cash flow continues to reduce at historical rates of 20.7% each year


Discover healthy companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.